A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition - Wikidata - wikimedia - TriplyDB

A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition

A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition

http://www.wikidata.org/entity/Q28828212

about

Inactivation of human DGAT2 by oxidative stress on cysteine residues Casein kinase 2 controls the survival of normal thymic and leukemic γδ T cells via promotion of AKT signaling.Dyrk1 inhibition improves Alzheimer's disease-like pathology.Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.Casein kinase 2 is a critical determinant of the balance of Th17 and Treg cell differentiation Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues.A Selective Biligand Inhibitor of CK2 Increases Caspase-3 Activity in Cancer Cells and Inhibits Platelet Aggregation.Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.A Requirement for Mena, an Actin Regulator, in Local mRNA Translation in Developing Neurons.MuvB: A Key to Cell Cycle Control in Ovarian Cancer.Altered development of dopaminergic neurons differentiated from stem cells from human exfoliated deciduous teeth of a patient with Down syndrome Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A

P2860

Q33898272-7457532F-FD60-4332-A8DE-BC05052A733D Q37710288-1888EB80-5C37-429D-A050-4413DF8B9B3A Q41628814-03393C81-FC29-4CD5-B76A-81C229F84D43 Q41696401-D9EBED16-54C7-4780-80AA-E6D851090BD3 Q42370428-208A4BF4-2D0A-4833-A987-ECA54DA33E4C Q47753817-D5B0AE75-A76D-4F4A-ADF3-A46CDA62E78A Q47911433-7E442CE1-7F06-4D27-B3CC-C241297E9D0D Q48001145-7C40B4DD-1BEB-4B08-8CF8-36D2236B21DB Q50307045-0EA8EC6B-4231-4108-B717-6A3AB40F2150 Q55286778-EE12D86F-3220-41E0-9341-2FF05B84BF71 Q57166427-6214261B-895E-4A15-999F-CE908EF2195C Q59127645-09A682A8-3AD3-4EB9-A3EB-AD23A3D45F83

P2860

A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition

http://www.wikidata.org/entity/Q28828212

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

A chemical with proven clinica ...... s in through DYRK1A inhibition

@ast

A chemical with proven clinica ...... s in through DYRK1A inhibition

@en

type

label

A chemical with proven clinica ...... s in through DYRK1A inhibition

@ast

A chemical with proven clinica ...... s in through DYRK1A inhibition

@en

prefLabel

A chemical with proven clinica ...... s in through DYRK1A inhibition

@ast

A chemical with proven clinica ...... s in through DYRK1A inhibition

@en

P1433

Q28828212-DE84903A-FC9C-4CDE-9D9D-888FF195E938

P1476

Q28828212-E2113804-6D8E-4ACD-9141-C7B0C533EAC8

P2093

Q28828212-4E73EC49-6C5C-4C6E-9E09-F464D4CBB48E

Q28828212-50E25998-9681-4765-8D28-B2ACAFE76731

Q28828212-610E5F05-19D9-4479-8458-79B25A75FE44

Q28828212-7F36387D-334E-4ED9-8964-48AFBC4EB49C

Q28828212-AC0E471E-FCF6-40D9-AEA1-B24E9D9ECCFD

Q28828212-B71C5672-1203-4BBF-9994-D624A06C5283

Q28828212-BFC7774A-C082-44FD-86B9-F1CD432DED07

Q28828212-C5A9ABF8-1FC8-48CD-AF35-E8F87A687BC2

Q28828212-CEA5D7C5-7861-4693-B5BC-2FF1A6BA5C6D

Q28828212-D20A0067-ACEA-4575-B1EC-FFE8E63CF0E8

P2860

Q28828212-07CB6757-F9E3-4C88-AE6B-F0B27CBEC848

Q28828212-1127BAF5-FA0E-4774-AA2D-E237E6F091BF

Q28828212-1906702E-ACD6-4195-ABC6-9CFF9F728055

Q28828212-19E628C8-5108-4D81-AEF3-0C9B67530298

Q28828212-1BB4C229-8567-4665-98F2-A1CDB898F518

Q28828212-20742708-9ACC-4DB8-B24F-008761B99CAD

Q28828212-213FD737-8DCA-40A6-A758-FFA2F74FE13B

Q28828212-2710DE26-369E-4CDC-94D7-3385E52EFEF5

Q28828212-2930F13D-3836-4CCA-9BD1-4ACDA534B0D3

Q28828212-2BE7C8F7-03A9-4EAB-9A99-674A3510E724

P304

Q28828212-809B019F-3E81-44D8-A542-68E0B066F4C0

P31

Q28828212-4DE9508A-3EBF-41B7-8BDC-6B8986350F59

P3181

Q28828212-1B94916A-930C-4118-A29B-EBDCF10456CC

P356

Q28828212-D08B5590-2991-4E1F-B7E4-088831484106

P407

Q28828212-97E35D7C-A592-4EFE-B0FA-0A925007130B

P433

Q28828212-7673865F-E5F8-444E-9255-B85B7CBEA61D

P478

Q28828212-545A0972-0649-44D0-85B3-508A068F1F9B

P50

Q28828212-0FC6036C-39E8-46F3-9E87-31593A75E46F

Q28828212-687BE5B2-9A98-43C9-8932-474B3666F1B8

P577

Q28828212-55BF59EE-91B6-40D4-ABD9-9D3C4A9D99A8

P698

Q28828212-16D37C51-38C7-45B3-B57B-F87C769A7C8E

P932

Q28828212-D0D8E554-2ED6-459D-B666-1D60F497A1E6

P3181

P356

P1433

Disease Models & Mechanisms

P1476

A chemical with proven clinica ...... s in through DYRK1A inhibition

@en

P2093

Ae-Kyeong Kim

http://www.w3.org/2001/XMLSchema#string

Hyeongki Kim

http://www.w3.org/2001/XMLSchema#string

Jeong-Soo Lee

http://www.w3.org/2001/XMLSchema#string

Kwangman Choi

http://www.w3.org/2001/XMLSchema#string

Kyu-Sun Lee

http://www.w3.org/2001/XMLSchema#string

Min-Sung Lee

http://www.w3.org/2001/XMLSchema#string

Mingu Kang

http://www.w3.org/2001/XMLSchema#string

Miri Choi

http://www.w3.org/2001/XMLSchema#string

Seung-Wook Chi

http://www.w3.org/2001/XMLSchema#string

So-Young Lee

http://www.w3.org/2001/XMLSchema#string

P2860

The importance of neuritic plaques and tangles to the development and evolution of AD

Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A

Structural basis of CX-4945 binding to human protein kinase CK2

Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing

Human minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome

Identification of a novel function of CX-4945 as a splicing regulator

Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice

Impaired spatial learning strategies and novel object recognition in mice haploinsufficient for the dual specificity tyrosine-regulated kinase-1A (Dyrk1A).

Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).

Riquiqui and minibrain are regulators of the hippo pathway downstream of Dachsous.

P304

839-848

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4616313

http://www.w3.org/2001/XMLSchema#string

P356

10.1242/DMM.025668

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27483355

http://www.w3.org/2001/XMLSchema#string

P932

5007978

http://www.w3.org/2001/XMLSchema#string